Redwood Scientific Technologies and TBX FREE: Why Natural Cytisine May Define the Next Generation of Nicotine Free Cessation
Share
For more than 40 years, the smoking cessation market has largely revolved around 1 basic idea: replace nicotine with more nicotine and hope the user eventually quits. Gum, patches, and lozenges have helped some people, but they do not change the central problem for many smokers and vapers. They still rely on nicotine.
Redwood Scientific Technologies is focused on a different path.
Through its TBX FREE and TBX VAPE FREE platforms, Redwood is developing nicotine free oral thin film technologies intended to help individuals transition away from combustible cigarettes, vaping products, and nicotine based dependency. The company’s approach is built around 2 core ideas. First, the active ingredient strategy focuses on natural botanical cytisine. Second, the delivery experience is designed around how smoking and vaping actually work in daily life: taste, ritual, craving, habit, and oral fixation.
That combination is what makes Redwood’s development strategy especially compelling.
Redwood’s TBX FREE platform is being developed around natural, non synthesized botanical cytisine, delivered through a sublingual dissolvable strip. Redwood’s science materials describe the platform as using “Natural cytisine derived from Laburnum anagyroides,” recognized in the HPUS, and delivered by sublingual dissolvable strip.[1]
This distinction matters because cytisine is not simply another general wellness ingredient. Cytisine is a naturally occurring botanical alkaloid that has been studied for decades as a smoking cessation agent. Redwood’s science materials explain that cytisine works by targeting the same brain receptor system that nicotine uses, specifically the α4β2 nicotinic acetylcholine receptors.[1]
In plain terms, nicotine creates dependency by repeatedly activating reward pathways in the brain. It binds to receptors, triggers dopamine activity, and reinforces the cycle that keeps smokers and vapers coming back. Redwood’s science materials describe this as the addiction loop, where the brain becomes physically dependent on nicotine to feel normal.[1]
Cytisine is studied because it interacts with that same receptor system in a different way. Redwood’s science materials describe cytisine as operating through a 2 part mechanism: partial agonist activity and competitive antagonist activity at the α4β2 nicotinic acetylcholine receptor.[1] As a partial agonist, cytisine is intended to provide enough receptor activity to help reduce withdrawal symptoms. As a competitive antagonist, cytisine occupies receptors so nicotine has fewer available places to bind, which may reduce the reward associated with smoking or vaping.
This is the scientific foundation behind Redwood’s product strategy.
To Redwood’s knowledge, Redwood believes it is uniquely positioned because it is pursuing this specific combination: a nicotine free cessation platform built around natural, non synthesized botanical cytisine, delivered through a sublingual oral thin film strip. This is not merely a different flavor or another version of a legacy cessation product. It is a different approach to the category.
The independent research around cytisine is significant.
In a placebo controlled trial published in The New England Journal of Medicine in 2011, cytisine showed stronger abstinence results than placebo. Redwood’s science materials summarize the study as reporting 12 month sustained abstinence of 8.4% for cytisine compared with 2.4% for placebo.[2]
In a later New England Journal of Medicine study involving 1,310 participants, cytisine was compared directly against nicotine replacement therapy. Redwood’s science materials summarize the published data as showing cessation at 1 month of 40% for cytisine compared with 31% for nicotine replacement therapy, and cessation at 6 months of 22% for cytisine compared with 15% for nicotine replacement therapy.[3] The same Redwood science document includes the quoted statement: “Cytisine was superior to NRT for smoking cessation at all time points measured.”[3]
For Redwood, the importance of this evidence is straightforward. The company is not attempting to build around an unknown active. It is developing around a natural active molecule with decades of scientific history, real world use, and independent clinical research.
The delivery format may be just as important as the active ingredient.
Smoking and vaping are not only chemical dependencies. They are behavioral routines. A smoker becomes attached to the break in the day, the physical habit, the flavor profile, the oral fixation, and the familiar moment of use. Vape users experience similar patterns, often with even more frequent access and a broader range of flavors and devices.
A cessation product that ignores those behavioral realities may miss a major part of the problem.
TBX FREE is being developed as an oral thin film strip that dissolves under the tongue. The format is intended to be portable, discreet, simple, and compatible with real world moments when cravings occur. Rather than relying on a legacy gum, patch, or lozenge format, Redwood is building a product experience intended to match modern consumer expectations while remaining nicotine free.
That is where Redwood’s opportunity becomes especially interesting.
The market is moving beyond cigarettes alone. Vaping has created a new generation of nicotine users. Traditional cigarette smokers still represent a massive global health challenge. At the same time, consumers, regulators, and healthcare systems are increasingly focused on reducing nicotine dependence rather than simply changing the form in which nicotine is delivered.
Redwood’s strategy aligns with that shift.
The company is not currently marketing or selling TBX FREE or TBX VAPE FREE. Redwood intends to complete controlled clinical validation before commercial launch and before making product specific efficacy claims. That discipline is important. The science around cytisine is strong, but Redwood’s product specific claims must be supported by Redwood’s own completed study work.
The larger story is clear.
The next generation of smoking and vaping cessation may not be defined by replacing nicotine with more nicotine. It may be defined by products designed to help users move away from nicotine altogether.
Redwood Scientific Technologies is positioning TBX FREE at the center of that future: natural botanical cytisine, nicotine free development, sublingual oral thin film delivery, and a user experience designed around the real behavioral structure of smoking and vaping.
That is why Redwood’s natural cytisine platform may represent one of the most compelling development stories in the next generation of nicotine free cessation.
Sources and References
[1] Redwood Scientific Technologies, The Science Behind TBX FREE, Redwood Science Combined v2. The document describes TBX FREE as using natural cytisine derived from Laburnum anagyroides, recognized in the HPUS, and delivered via sublingual dissolvable strip.
[2] West et al., New England Journal of Medicine, 2011. Redwood’s science materials summarize the study as reporting 12 month sustained abstinence of 8.4% for cytisine compared with 2.4% for placebo.
[3] Walker et al., New England Journal of Medicine, 2014. Redwood’s science materials summarize the study as reporting cessation at 1 month of 40% for cytisine compared with 31% for nicotine replacement therapy, and cessation at 6 months of 22% for cytisine compared with 15% for nicotine replacement therapy.
[4] Cochrane Network Meta Analysis, 2024, as summarized in Redwood’s science materials. Redwood’s science materials state that cytisine ranked #3 globally alongside varenicline in a network meta analysis covering more than 150,000 subjects.
[5] World Health Organization, Essential Medicines List 2025, as summarized in Redwood’s science materials. Redwood’s science materials state that cytisine was formally added to the WHO Model List of Essential Medicines 2025.
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.